Phosphodiesterase type 5 inhibitors: discovery and therapeutic utility

被引:21
作者
Rotella, DP [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA
关键词
D O I
10.1358/dof.2001.026.02.658842
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
[No abstract available]
引用
收藏
页码:153 / 162
页数:10
相关论文
共 43 条
[41]  
WOOD A, Patent No. 0995750
[42]   Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors [J].
Xia, Y ;
Chackalamannil, S ;
Czarniecki, M ;
Tsai, HG ;
Vaccaro, H ;
Cleven, R ;
Cook, J ;
Fawzi, A ;
Watkins, R ;
Zhang, HT .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (26) :4372-4377
[43]   Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene [J].
Yanaka, N ;
Kotera, J ;
Ohtsuka, A ;
Akatsuka, H ;
Imai, Y ;
Michibata, H ;
Fujishige, K ;
Kawai, E ;
Takebayashi, SI ;
Okumura, K ;
Omori, K .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 255 (02) :391-399